"L'azienda ospedaliera "San Martino" è integrata con l'Università degli studi di Genova, facoltà di medicina e chirurgia, con il compito di realizzare sia gli obiettivi di assistenza previsti dalla programmazione sanitaria nazionale e regionale, che gli obiettivi assistenziali ai fini dell'integrazione tra didattica, ricerca ed assistenza. L'obbiettivo aziendale è quello di rispondere al "bisogno di salute" del cittadino, attraverso tutte le più appropriate capacità cliniche, diagnostiche e terapeutico-assistenziali; in particolare è centro di eccellenza di rilievo nazionale per: i trapianti, l'ematologia, la neurochirurgia, la cardiologia e la cardiochirurgia."

During the past decade, IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 28 clinical trials were completed, i.e. on average, 133.3% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 17 clinical trials were completed. i.e. 425% of trials that started reached the finish line.

Out of the total clinical trials conducted in "IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A" #1 sponsor was "Hoffmann-La Roche" with 23 trials, followed by "IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy" with 10 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 9 trials sponsored, "AGC Biologics S.p.A." with 4 trials sponsored and "Gruppo Oncologico del Nord-Ovest" with 4 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A" #1 collaborator was "AstraZeneca" with 2 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 2 trials as a collaborator, "ASL TO4, Chivasso" with 1 trials as a collaborator and "Aventis Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include 29 different institutions and companies that were collaborators in the rest 39 trials.

According to Clinical.Site data, the most researched conditions in "IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A" are "Breast Cancer" (13 trials), "Colorectal Cancer" (3 trials), "Malignant Melanoma" (3 trials), "Malignant Mesothelioma" (3 trials) and "Non Small Cell Lung Cancer" (3 trials). Many other conditions were trialed in "IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A" in a lesser frequency.

Most popular intervention types in "IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A" are "Drug" (63 trials), "Other" (7 trials), "Procedure" (5 trials), "Biological" (3 trials) and "Radiation" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Docetaxel" (7 trials), "Atezolizumab" (6 trials), "Carboplatin" (5 trials) and "Paclitaxel" (5 trials). Other intervention names were less common.

The vast majority of trials in "IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A" are 62 trials for "All" genders, 8 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A". undefined are not yet recruiting, 4 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 41 completed trials in IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, 1 suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, 0 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 42 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".